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Objective: To develop an infection-resistant polytetrafluoroethylene (PTFE) vascular graft for potential clinical use in 
grafting in sites of bacterial contamination and in replacement ofthe infected grafts. 
Setting: Experimental study in rabbits 
Materials and methods: An antibiotic ofloxacin (OFLX) was bonded to a sheet of PTFE by impregnation, which was cut 
and twisted into fine threads. The in-vitro antibacterial ctivity of OFLX-PTFE thread was determined by measuring the 
zone of growth inhibition against Escherichia coli. The thread was spirally coiled around a ridged outerwall PTFE to make 
the OFLX-PTFE graft. OFLX-PTFE graft or control graft was interposed in the inferior vena cava (IVC) of rabbits and 
the entire graft was covered with fibrin containing a fixed number of E. coli. Three or 7 days after the grafting, the grafts 
with perigrafl tissue were harvested and subjected to bacteriological studies. 
Results: In spite of early phase rapid elution of OFLX, a significant antibacterial ctivity was retained for more than 2 
weeks. The antibacterial ctivity of OFLX-PTFE threads implanted in the subcutaneous space of rabbits decreased to487o 
after 24 h and to approximately 17o after a week. The swab culture of all the control grafts was positive, while only one of 
13 PTFE-OFLX grafts was positive. The number of viable bacteria in the perigraft issue of OFLX-PTFE grafts was 
remarkably low in comparison with that of control grafts. Thus, the OFLX-PTFE grafts exhibited a marked in-vivo 
antibacterial ctivity. 
Conclusion: By a unique method, it was possible to furnish PTFE graft with an excellent infection-resistant property, 
without affecting the original biological behaviour. 
Key Words: Graft infection; Polytetrafluoroethylene; Ofloxacin; Animal model. 
Introduction 
In view of the increasing number of vascular econ- 
structions using synthetic vascular prostheses, the 
vascular prosthetic graft infection remains the most 
serious complication in vascular surgery, and often 
results in loss of organ function, limb and life. To date, 
a large number of clinical ~ and experimental 2"3studies 
have suggested that prophylactic intravenous antibi- 
otics reduce the incidence of graft infections, and 
prophylactic administration has been widely prac- 
tised. Nevertheless, the infection still occurs in a 
considerable number of patients and the infected graft 
may have to be completely removed in order to 
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control the infection. Most of the infections are due to 
a contamination at the time of implantation, 4 yet 
vascular prosthetic reconstruction may be required at 
possibly contaminated sites associated with in situ 
replacement of the infected graft. Moreover, with the  
increase in indications for vascular surger)5 prosthetic 
reconstructions may be tried simultaneously with 
non-aseptic operations such as gastrointestinal or 
gynaecological surgery. Under these circumstances, 
considerable fforts have been made to develop an 
infection-resistant vascular prosthesis. As one of the 
approaches, bonding of antimicrobial agents to pros- 
thetic materials has been attempted, by various 
techniques uch as fixation with surfactants, ~-9 syn- 
thetic or biological glue, l°'n collagen release, 12 silver 
containing antibiotics, 13-1s passive method by preclot- 
ting, 16 soaking into a protein-sealed textile graft 17'18 
and thermofixation. 19 The purpose of the present 
study was to furnish the polytetrafluoroethylene 
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(PTFE) graft with an infection-resistant property by a 
novel modification with antibiotic bonded PTFE 
thread without impairing the original biological 
properties. 
study and also for subcutaneous implantation, the 
OFLX-PTFE thread (7.5 cm) was coiled around a 6 × 
6 mm PTFE sheet with identical specification to the 
PTFE tube graft (Technograft®), as shown in Fig. la. 
Materials and Methods 
Bonding of ofloxacin (OFLX) to PTFE 
OFLX 2° was kindly provided by Dai-ichi Pharmaceuti- 
cal Company, Tokyo. OFLX (200-600rag) was sus- 
pended in 4 ml of a 2.5% solution of polylactic acid (50 
Kd, Polyscience Co., Warrington, PA, U.S.A.) in 
dioxane (Wako Pure Chemical Co., Osaka, Japan). The 
solution was impregnated onto two kinds of 10 × 
25cm PTFE sheets (LUP-300 and UP-005) obtained 
from Sumitomo Electric Industries. The thickness was 
identical (40/xm), but the pore size of LUP-300 and 
UP-005 was 3/xm and 0.05/xm, respectively. After air- 
drying completely, the PTFE sheet was cut into strips 
(0.5 cm wide) and lightly twisted into a form of thread. 
Then, using dioxane as adhesive, 10 cm of the OFLX- 
PTFE thread or control thread was spirally coiled 
around a 3 cm long ridged outerwall PTFE tube graft 
(same structure as Technograft®, a product of Sumi- 
tomo Electric Industries) with specifications as fol- 
lows. The inner diameter was 3 mm and the internodal 
distance was 30/.~m. The wall thickness changed every 
0.5ram and the thickness of the valley and ridge 
portion was 0.3mm and 0.5mm, respectively. The 
OFLX-PTFE graft is shown in Fig. lb. For in vitro 
Determination ofantibacterial activity 
Escherichia coli, JM109, a stock culture in the Depart- 
ment of Microbiolog~ Osaka University Medical 
School was used as a representative bacterial strain in 
the entire experiment. In vitro and in vivo antibacterial 
activity of OFLX-PTFE thread coiled around the PTFE 
sheet was determined by measuring the zone of 
growth inhibition against he E. coli and interpolating 
the value from a standard curve described below. Ten 
microlitres of known concentration of OFLX were 
adsorbed onto a filter paper with a diameter of 6 mm. 
The paper, containing various doses of OFLX, was 
placed on a nutrient agar plate (consisting of 1% Bacto 
Tryptone, 0.5% Bacto Yeast Extract, 0.5% NaC1 and 
1.5% Bacto Agar, Difco, Detroit, MI, U.S.A.) on which 
3 × 107 of the bacteria was inoculated. After incuba- 
tion at 37°C for 12 h, the zone of growth inhibition, 
(diameter of the inhibitory zone -6 ) /2mm,  was 
determined (Fig. 2). 
In vitro experiments 
Influence of various sterilisation procedures of OFLX- 
PTFE on the antibacterial activity 
Non-treated OFLX-PTFE threads and those sterilised 
by autoclave (at 121°C for 15 min and drying at 60°C), 
Fig. 1. Biomaterial used for the study. (a) OFLX-bonded PTFE thread 
coiled around PTFE sheet for subcutaneous implantation. (b) PTFE 
tube graft spirally coiled by OFLX-bonded PTFE thread. The 
detailed specifications are described in Materials and Methods. 
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Fig. 2. Correlation between the inhibitory zone on disc and amount 
of OFLX added on the agar containing 3 × 10 7 E. coli. Vertical bars 
indicate S.D. (n = 3). 
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immersion into 70% ethanol for 5 min, or ethylene 
oxide gas (EO 20%/CO2 80%, i kg/cm 2 for 6 h) were 
placed on the nutrient agar plates onto which 3 × 107 
of E. coli had been inoculated and incubated for 12 h at 
37°C. The size of the inhibitory zone of the treated 
samples was compared with that of the non-treated 
ones. 
Release of OFLX from OFLX-PTFE in saline 
Two kinds of OFLX-PTFE threads (UP-005 and LUP- 
300, initial OFLX dose; 50 mg/ml) were coiled around 
the PTFE sheet as described above. Eight of each of the 
threads were incubated in saline (10ml, 37°C). Two 
threads from each group were removed from the 
saline at days 1, 3, 5, 9, 14. The residual antibacterial 
activity was determined by comparing zone of growth 
inhibition with the standard curve. Three different 
doses of OFLX (50, 100 and 150mg/ml) were bonded 
to PTFE sheets (LUP-300) as described above to obtain 
OFLX-PTFE threads containing different amounts of 
OFLX. Also, OFLX-PTFE threads with different 
lengths were prepared (1.9, 3.75, 7.5cm). These 
threads were subjected to immersion in saline and to 
determination of the residual activity. The OFLX- 
PTFE thread (initial OFLX dose; 50mg/ml) was 
autoclaved as described above and the sterilised 
thread was likewise subjected to the determination of
residual activity upon immersing in saline. 
In vivo experiments 
Residual antibacterial ctivity of OFLX-PTFE threads after 
implantation i to the subcutaneous space 
Albino rabbits weighing approximately 2.5 kg, 
obtained from Kitayama Labes Co., Ltd. (Nagano, 
Japan), were used in this study. They were fed with a 
standard diet for at least one week before use. The 
animals were anaesthetised with an intravenous 
administration of sodium pentobarbiturate (30mg/ 
kg) via the ear vein. An additional dose was given to 
prevent hem from suffering any further discomfort. 
To study in vivo release of OFLX, OFLX-PTFE threads 
coiled around the PTFE sheet were implanted in the 
subcutaneous pockets (1 cm) on the back of rabbits 
(four pockets in each rabbit). The wound was closed in 
one layer with 4-0 silk. At 1, 3 and 7 days after 
implantation, the threads were harvested under sterile 
conditions (n = 4 each). The specimens were placed on 
E. coli (3 × 107) inoculated agar plates and incubated 
at 37°C for 12 h. The residual antibacterial ctivity of 
the specimen was determined as described above. 
In vivo antibacterial activity of OFLX-PTFE and control 
PTFE graft 
Prior to the implantation of OFLX-PTFE or control 
graft into IVC of rabbits, the bacterial solution for 
perigraft inoculation was prepared. Bacterial cultures 
of 2 × 108 CFU growing logarithmically were precipi- 
tated by centrifugation at 15000 rpm for 10 rain, and 
mixed with 0.4 ml sterile fibrinogen solution (Beriplast 
P, Hoechst Japan, Tokyo). The technique of graft 
implantation was basically similar to that used in our 
previous study. 21 Briefl)~ through a median lapar- 
otom)~ the infrarenal IVC was gently exposed. After 
systemic heparinisation (sodium heparin, 100U/kg), 
two small atraumatic lamps were placed on the IVC 
just below the renal veins and just above the iliac 
bifurcation. A I cm segment of IVC was resected and 
then replaced with a 3 cm long OFLX-PTFE or control 
graft. The anastomoses were carefully constructed 
using an interrupted suture of 7-0 polypropylene. 
After haemostasis was secured, the fibrinogen solu- 
tion containing E. coli (2 × 108, 0.4ml) and freshly 
prepared 100 U/ml  thrombin calcium solution (0.4 ml) 
were simultaneously instilled around the entire sur- 
face of the graft. After the complete gelation of 
fibrinogen, the retroperitoneum was tightly closed 
with 7-0 polypropylene and the abdomen was closed 
in one layer. At days 3 and 7 after the implantation, the 
rabbits were anaesthetised and the abdomen was 
reopened. The abdominal cavity was thoroughly 
examined with respect o manifestation of infection. 
To examine for the presence or absence of viable 
bacteria round the grafts, swab cultures of the grafts 
were made as follows. The external surfaces of the 
graft were rubbed on nutrient agar plates and the 
grafts were also put on agar plates. These plates were 
incubated at 37°C for 12 h. To examine the number of 
viable bacteria in perigraft issues emi-quantitatively, 
the perigraft tissues were weighed aseptically and 
homogenised with an equal volume (ml/g) of nutrient 
broth by a homogeniser (pellet mixer from Toho Co. 
Ltd., Tokyo, Japan). The homogenates were diluted 
with nutrient broth serially and plated on nutrient 
agar plates. 
All animal care and procedures were performed 
at the Animal Experimental Center of Osaka Uni- 
versity Medical School. Animal protocols were 
approved by the Osaka University Medical School 
Animal Committee and conformed to the guidelines 
set forth by the Osaka University Medical School. 
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Statistical analysis 
Data of in vivo positivity of abscess formation and 
swab culture were compared using Fisher's extract 
probability test. Since distribution of bacterial number 
was grossly heterogeneous, the non-parametric Mann- 
Whitney U-test was used for comparing the CFU 
value in perigraft issue. 
Results 
In vitro study 
Influence of sterilisation 
The antibacterial ctivity of non-sterilised OFLX-PTFE 
threads and those sterilised by three different methods 
was determined as described in Materials and Meth- 
ods. The inhibitory zone of the non-sterilised OFLX- 
PTFE thread was 35 mm/7.5 cm. The inhibitory zones 
of the sterilised threads were as follows; autoclave 
36 mm, ethanol immersion 33 mm, ethylene oxide gas 
exposure 35mm. Thus, the antibacterial activity of 
OFLX-PTFE threads was not affected by any of the 
sterilisation methods used. 
Release of OFLX from OFLX-PTFE threads 
As shown in Fig. 3, the initial antibacterial ctivity was 
higher in the threads made of LUP-300 than those of 
UP-005. The residual antibacterial ctivity after incu- 
bation in saline was also higher in LUP-300. Therefore, 
in the subsequent experiments, LUP-300 was exclu- 
sively used to prepare OFLX-bonded or control 
threads. The initial antibacterial activity of OFLX- 
PTFE thread was not proportional to the initial 
concentration of OFLX in the reaction mixture (data 
not shown). As there was no significant difference in 
the residual antibacterial ctivity of the three groups 
in saline up to 14 days (data not shown), 50mg/ml 
OFLX solution was used for the subsequent bonding. 
The antibacterial activity of OFLX-PTFE thread 
increased proportionally with the length (data not 
shown). The antibacterial activity of the autoclaved 
OFLX-PTFE threads incubated in saline for 6 h and for 
24 h were 28.4% and 13.6% of the initial amount, 
respectively, indicating rapid liberation of the bonded 
OFLX at an early stage (Fig. 4). The liberation after day 
2 up to day 14 was very gradual and an activity 
equivalent to 5.8 ~g of OFLX was recovered from the 
PTFE even after 2 weeks (Fig. 4). 
In vivo experiments 
Residual antibacterial ctivity of OFLX-PTFE threads after 
implantation into the subcutaneous space of rabbits 
The antibacterial ctivity of OFLX-PTFE threads kept 
in the subcutaneous space for 24 h decreased to 
approximately 50% and by day 3 rapidly decreased to 
1% of the initial activity as shown in Fig. 5. However, 
the activity equivalent o 1.4-2.2/zg of OFLX was 
maintained for at least 7 days. Even with this amount 
of OFLX, a significant value of inhibitory zone was 
obtained, as shown in Fig. 5. 
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Fig. 3. Antibacterial ctivity of OFLX-PTFE threads made of PTFE 
with different pore sizes; 3/~m LUP-300 (@), 0.05/~m UP-005 (O). 
Results were expressed as the mean values (n = 2) comparable to the 
amount of OI~LX. 
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Fig. 4. Antibacterial activity of autoclaved OFLX-PTFE threads 
incubated in saline. The results were expressed in two parameters; 
left vertical axis, mean values of the inhibitory zones (©), right 
vertical axis, mean values comparable to the amount of OFLX (@). 
Vertical bars indicate S.D. (n = 3). 
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In vivo antibacterial activity of OFLX-bonded PTFE 
grafts 
There was no sign of dissemination of infection into 
the peritoneal cavity in any of the rabbits studied. All 
the grafts were patent at the time of harvest. As 
summarised in Table 1, at day 3, the OFLX-bonded 
PTFE grafts exhibited marked infection-resistant prop- 
erties, judging from the incidence of abscess forma- 
tion, result of swab culture and semi-quantitative 
assay of bacteria in the perigraft issues. As shown in 
Fig. 6, the actual number of bacteria in the perigraft 
tissue of OFLX-PTFE grafts was approximately 5000 
times less than that in control grafts at day 3. The 
OFLX-PTFE grafts at day 7 still exhibited significant 
infection-resistant properties, as evidenced by the 
incidence of abscess formation, result of swab culture 
and semi-quantitative assay of bacteria in the perigraft 
tissues. RemarkablN the bacteria recovered from the 
OFLX-PTFE grafts at day 7 were below the detection 
limit (less than 102 CFU/g perigraft issue) as shown 
in Fig. 6. 
Discuss ion  
In most cases, synthetic vascular graft infection is 
provoked by bacterial seeding on the outer wall of the 
graft at the time of implantation. 2~' This fact may well 
explain the reason why intravenous administration of
various antibiotics has its limits in preventing or 
treating graft infection. 9'23'24 Topical application of 
antibiotics directly to the graft has been attempted, but 
the beneficial effect has not been proven because of the 
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Fig. 5. Antibacterial activity of OFLX-PTFE threads implanted into 
the subcutaneous space of rabbits. The values were expressed in two 
parameters as in Fig. 4: the inhibitory zones (©) and the amount of 
OFLX, (0). Vertical bars indicate S.D. (n = 4). 
rapid elution of the antibioticJ 2'a5 The topical applica- 
tion of antibiotic would be effective if it could be kept 
at a significant concentration for a longer periodJ °'26 A 
large number of investigators have attempted to 
develop an antibiotic-bound vascular prosthesis capa- 
ble of exhibiting an antibacterial ctivity over a long 
period of time. 5-19 In most of the methods, the 
antibiotics and carrier agent or glue are fixed not only 
to the outer surface but also in the wall and on the 
inner surface of the vascular prosthesis. This condition 
may impair the innate histocompatibility and antith- 
rombogenecityY Furthermore, the healing of vascular 
prosthesis may be hampered when the porous wall 
structure is filled with the carriers. Considering these 
problems, we made an attempt o furnish the PTFE 
graft with an infection-resistant property only in the 
perigraft area where bacteria grow. This was achieved 
by winding antibiotic-bound PTFE thread around a 
PTFE tube graft. To date, such an invention used to 
furnish an infection-resistant property to vascular 
prosthesis has not been reported. Among the various 
new quinolone antibiotics, OFLX was selected for 
bonding in this studN as this agent exerts potent 
antimicrobial activity against methicillin-resistant 
Staphylococcus aureus as well as other Gram-positive 
and Gram-negative bacteria including E. coli. 2° Instead 
of a conventional smooth-surface PTFE graft, a ridged 
outer wall PTFE was used in the experiment, because 
the precise coiling on the tube graft may be achieved 
with excellent antikinking and incollapsible proper- 
ties, without any external support. 2s 
Judging from the data on the in vitro decay of 
antibacterial activitN the elution of OFLX from the 
thread may be divided into two phases; rapid release 
within 24 h followed by gradual release up to 2 weeks. 
Decay patterns comparable to ours have been also 
documented in other reports. 7'29 The rapid release 
(more than 80% within 24 h) may be partly due to the 
presence of loosely-bound OFLX in the outer surface 
of the thread and the subsequent slow release might 
be due to the elution of OFLX from the void space on 
the inner structure of the thread. It was not possible to 
compare the release rate directly with those in other 
reports due to differences in methodology. However, 
the elution of OFLX from PTFE was much slower than 
that of oxacillin bound to PTFE by benzalkonium 5 and 
chloramphenicol r amikacin bonded to Dacron by 
collagen. 29 Our data may be comparable with that of 
penicillin G bonded to PTFE by tridodecylmethy- 
lammonium. 6 As the liberation of non-covalently 
bonded agents from biomaterials may be affected not 
only by the carrier but also by the property of the 
agent itself, such as its chemical structure and "hydro- 
phobicitN the release rate may differ significantly 
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Table 1. In vivo effects of OFLX-PTFE grafts on abscess formation, swab culture and number of bacteria. 
Number of bacteria 
n Abscess formation Swab culture in perigraft issue (CFU/g) 
3 days 
Control 5 5/5" 5/5"* 2.1x106t 
OFLX-PTFE 9 0/9" 1/9"* 4.3x102t 
7 days 
Control 4 4/4"** 4/4"*** 9.2x103tt 
OFLX-PTFE 4 2/4*** 0/4**** > lxl0Ztt 
Fishers extract probability test (asterisks), Mann-Whitney U-test (daggers). 
*, **, t; p < 0.01. 
****, fI; p < 0.05. 
***; NS.  
depending on the agent bonded to the prosthesis. 5'28 
Elution of OFLX from OFLX-PTFE threads kept in 
living tissue was rather slow for the initial 24 h in 
comparison with the in vitro elution. The subsequent 
elution, however, was much faster than the elution in 
vitro. The elution of the agents bound to biomaterials 
may be affected by a number of factors, such as the 
presence of body fluid containing various lipids acting 
as surfactant and cellular infiltration and uptake. The 
relatively slow elution within 24 h in our study cannot 
be fully explained, but the subsequent rapid decay of 
the activity may be due to the cellular intake of OFLX. 
The elution rate in our study, however, was much 
slower than that of penicillin- or cefazolin-bound 
Dacron. 7The in vivo elution of silver antibiotic PTFE 
has been reported to be very slow (approximately 20% 
at I week), but this result was based on the radioactiv- 
ity of 11°Ag13 and may not actually reflect the actual 
amount of antibiotic. Despite the rapid in vitro elution 
of the bonded agents, most of them, grafte d in 
animals, exhibited excellent in vivo infection-resistant 
properties. 9'1°'13 The present OFLX-PTFE grafts also 
showed excellent infection-resistant properties at days 
3 and 7. The findings at day 3 seemed to be more 
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Fig. 6. In vivo antibacterial ctivity of OFLX-PTFE and control PTFE 
grafts implanted into IVC of rabbits. The values were expressed in 
log 10 (CFU/g perigraft tissue): The vertical bars indicate SD 
(n = 4-9). 
remarkable than those at day 7 in terms of difference 
in bacterial number and gross appearance of infection. 
A precise comparison between the two, however, may 
not be possible, because the bacterial growth at day 7 
of the control group was apparently suppressed by the 
endogenous immune system. The present results may 
also suggest hat the initial suppression of infection 
may be beneficial to the control of subsequent devel- 
opment of graft infection as has been suggested. 22'~3 
However, it was also possible that a small but 
significant amount of OFLX remaining in the graft was 
sufficient o control the bacterial growth in our model. 
From these observations in the present studN it was 
concluded that OFLX-PTFE grafts, made by a unique 
but simple method, exhibit an excellent in vivo 
antibacterial ctivity. Considering its possible clinical 
application, the OFLX-PTFE graft may have various 
advantages, such as sterilisability, adjustability and 
availability. Infection-resistant grafts made by soaking 
rifampicin into protein-sealed Dacron graft have been 
already utilised in clinical patients at high risk of 
developing infection. 18 The outcome is promising but 
this ingenious approach cannot apparently be applied 
to vascular prosthesis made of PTFE. The next step to 
clinical application would be the use of OFLX-PTFE 
threads as an infection-resistant suture, which may be 
required in various contaminated surgical 
procedures. 
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